GlobeNewsWire
14 May 2026, 20:05 UTC · 18w ago
Verdict
Headline takes no side. We score ZYME +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 74% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Zymeworks has authorized a new share repurchase program of up to $125 million of its common stock through May 14, 2026.
So whatBuybacks typically increase share price by reducing supply and signaling management's confidence in the company's valuation.
More positive than 91% of claims this week
Zymeworks terminated its 2025 repurchase program after spending $102.3 million to buy back approximately 4.2 million shares.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 53% of claims this week
Which stocks this story touches
More positive than 74% of ticker scores this week
The company announced a new $125 million share repurchase program, indicating strong financial capacity and a commitment to returning value to shareholders.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as a partner for the commercialization of zanidatamab with no new material developments.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as a partner for the commercialization of zanidatamab with no new material developments.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
More positive than 78% of relationship scores this week
[mutual] Zymeworks entered into an agreement with Jazz Pharmaceuticals granting exclusive rights to develop and commercialize zanidatamab in certain territories.
+11.2%
Price agrees with the score
$26.64 vs $23.96 close before publication (May 14) · not market-adjusted
ZYME chart →
